Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of PG4 vs 20vPnC in Healthy Infants
NCT07573462Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of PG4 in pneumococcal disease (2 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants reporting local reactions, Percentage of participants reporting systemic events and 2 more. Started May 2026; status: recruiting.
02
Drugs
PG4
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07573462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07573462.